-
-
-
-
-
-
-
Vertex stock jumps as rival cystic fibrosis drug fails trial
-
-
-
-
-
-
-
Vertex Pharma (VRTX) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY26 Revenue Guidance
-
-
-
-
-
-
-
Vertex (VRTX) Reiterated at Overweight by Cantor Fitzgerald; Crinetics Acquisition Announced
-
-
-
-
-
-
-
Vertex presents positive data for ALYFTREK in young cystic fibrosis patients
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Vertex (VRTX)
-
-
-
-
-
-
-
Vertex (VRTX) PT Lowered to $541 at RBC Capital
-
-
-
-
-
-
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
458,127 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

